View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 24, 2019

Olympus launches new device to treat severe emphysema

Medical devices firm Olympus has launched a new Spiration Valve System (SVS) in the US for the treatment of severe emphysema, a type of chronic obstructive pulmonary disease (COPD).

Medical devices firm Olympus has launched the new Spiration Valve System (SVS) in the US for the treatment of severe emphysema, a type of chronic obstructive pulmonary disease (COPD).

The endobronchial valve is an umbrella shaped device that can be placed in targeted airways of the lung. It is designed to redirect air from diseased parts to healthier parts, in turn improving breathing.

“The Spiration Valve can be used to help adults suffering from shortness of breath and hyperinflation due to severe emphysema in the lung regions with evidence of low collateral ventilation.”

Olympus said that treatment with the new device may cause volume reduction in the treated part and enable the healthier tissue in the remaining part of the lung to work more effectively.

The Spiration Valve can be used to help adults suffering from shortness of breath and hyperinflation due to severe emphysema in the lung regions with evidence of low collateral ventilation.

Olympus America Endoscopy division group vice-president Kurt Heine said: “We are very excited to add the Spiration Valve System to our broad portfolio of respiratory devices and bronchoscopes.

“The SVS provides physicians a minimally invasive option for treating severe emphysema, allowing patients to find relief from debilitating symptoms.”

SVS secured approval from the US Food and Drug Administration (FDA), which reviewed findings from the EMPROVE clinical trial performed in patients with severe emphysema.

Patients treated with the device were observed to experience statistically significant and clinically meaningful improvements in lung function and quality of life, when compared to standard of care.

In addition, the device is said to offer a favourable risk benefit profile and a short procedure time.

Serious adverse events observed during the EMPROVE trial include COPD exacerbations, pneumothorax, pneumonia and death.

Besides the US, Spiration Valve is approved in the European Union (EU) markets, Australia and New Zealand for the treatment of emphysema.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU